Castle Biosciences (CSTL) Gross Profit (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Gross Profit data on file, last reported at $63.1 million in Q1 2026.

• Quarterly Gross Profit fell 11.81% year-over-year to $63.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $264.7 million (down 6.91% YoY) and the FY2025 annual result came in at $273.2 million, changed 0.49% from the prior year.
• Gross Profit retreated to $63.1 million in Q1 2026 per CSTL's latest filing, from $68.7 million in the prior quarter.
• The five-year high for Gross Profit was $72.5 million in Q2 2024, with the low at $20.9 million in Q1 2022.
• Average Gross Profit over 5 years is $52.2 million, with a median of $59.1 million recorded in 2024.
• Year-over-year, Gross Profit surged 86.33% in 2023 and declined 11.81% in 2026.
• Castle Biosciences' Gross Profit stood at $28.8 million in 2022, then soared by 86.33% to $53.7 million in 2023, then surged by 30.6% to $70.1 million in 2024, then decreased by 2.04% to $68.7 million in 2025, then slipped by 8.08% to $63.1 million in 2026.
• Business Quant data shows CSTL's Gross Profit at $63.1 million in Q1 2026, $68.7 million in Q4 2025, and $64.3 million in Q3 2025.